New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePE-22-28 vs Dermorphin

PE-22-28 vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
PE-22-28
Recovery & Repair
Dermorphin
Summary
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
Relatively short; CNS effects may persist due to neurogenic mechanisms
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
SubQ, Intranasal
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
200–400 mcg
Not established for human use; research doses vary widely
Frequency
Once daily
Not established
Key Benefits
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With